Genetically modified mesenchymal stem cells for improved islet transplantation.
Genetically modified mesenchymal stem cells for improved islet transplantation.
复制标题
DOI：
10.1021/mp200135e
复制
发表时间：
2011-10-03
影响因子：
4.9
通讯作者：
Mahato RI
中科院分区：
文献类型：
--
作者：
Wu H;Ye Z;Mahato RI
近年来，成体干细胞用于治疗目的取得了巨大成功。在几种类型的成体干细胞中，来源于骨髓（BM）和其他来源的间充质干细胞（MSC）由于其在治疗多种疾病中的治疗潜力而在基础研究和临床应用中受到欢迎。由于其组织再生潜力和免疫调节作用，近年来在胰岛移植中，MSC被用作基于细胞的治疗，以促进血管再生，增加胰腺β细胞增殖和避免同种异体排斥反应。利用基因治疗的最新进展，基因修饰的MSC可以进一步增强和扩大原代MSC的治疗益处，同时保留其干细胞样性质。本文就目前胰岛移植成功的障碍进行综述，并探讨原代间充质干细胞在胰岛移植中的潜在作用
The use of adult stem cells for therapeutic purposes has met with great success in recent years. Among several types of adult stem cells, mesenchymal stem cells (MSCs) derived from bone marrow (BM) and other sources have gained popularity for basic research and clinical applications because of their therapeutic potential in treating a variety of diseases. Because of their tissue regeneration potential and immune modulation effect, MSCs were recently used as cell-based therapy to promote revascularization, increase pancreatic β-cell proliferation and avoid allograft rejection in islet transplantation. Taking advantage of the recent progress in gene therapy, genetically modified MSCs can further enhance and expand the therapeutic benefit of primary MSCs while retaining their stem-cell like properties. This review aims to gain a thorough understanding of the current obstacles to successful islet transplantation and discusses the potential role of primary MSCs before or after genetic modification in islet transplantation
登录
查看更多内容
DOI：
10.1016/j.bbrc.2004.11.059
发表时间：
2005-01-21
影响因子：
3.1
作者：
Abdallah, BM;Haack-Sorensen, M;Kassem, M
通讯作者：
Kassem, M
影响因子：
2.6
作者：
Bartholomew, A;Sturgeon, C;Hoffman, R
通讯作者：
Hoffman, R
影响因子：
4.9
作者：
Cheng, Guofeng;Zhu, Lin;Mahato, Ram I.
通讯作者：
Mahato, Ram I.
影响因子：
5.1
作者：
Cheng, K;Fraga, D;Mahato, RI
通讯作者：
Mahato, RI
影响因子：
2
作者：
Dinarvand, Peyman;Hashemi, Seyed Mahmoud;Soleimani, Masoud
通讯作者：
Soleimani, Masoud